Seres Therapeutics Inc (MCRB) Shares Bought by Northern Trust Corp

Northern Trust Corp raised its stake in shares of Seres Therapeutics Inc (NASDAQ:MCRB) by 16.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 235,766 shares of the biotechnology company’s stock after acquiring an additional 32,875 shares during the quarter. Northern Trust Corp owned approximately 0.58% of Seres Therapeutics worth $2,664,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MCRB. Geode Capital Management LLC lifted its holdings in shares of Seres Therapeutics by 5.8% during the 1st quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock valued at $1,874,000 after purchasing an additional 9,060 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Seres Therapeutics by 24.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 44,418 shares of the biotechnology company’s stock valued at $501,000 after purchasing an additional 8,851 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Seres Therapeutics in the 2nd quarter worth $236,000. Vanguard Group Inc. raised its stake in Seres Therapeutics by 7.1% in the 1st quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock worth $17,645,000 after acquiring an additional 103,456 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in Seres Therapeutics by 5.1% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 91,049 shares of the biotechnology company’s stock worth $1,027,000 after acquiring an additional 4,446 shares during the last quarter. 77.83% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Inc (NASDAQ MCRB) traded down $0.34 during mid-day trading on Tuesday, reaching $9.85. The company had a trading volume of 186,931 shares, compared to its average volume of 207,145. The company has a debt-to-equity ratio of 0.11, a quick ratio of 6.53 and a current ratio of 6.53. Seres Therapeutics Inc has a 12 month low of $8.85 and a 12 month high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.22. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The business had revenue of $23.00 million for the quarter, compared to analyst estimates of $17.29 million. During the same period last year, the company posted ($0.46) EPS. The business’s revenue was up 76.9% on a year-over-year basis. analysts expect that Seres Therapeutics Inc will post -2.33 earnings per share for the current year.

A number of brokerages recently issued reports on MCRB. Zacks Investment Research upgraded Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Tuesday, December 5th. CIBC assumed coverage on Seres Therapeutics in a research note on Friday, October 13th. They set an “outperform” rating and a $19.00 price objective for the company. Oppenheimer assumed coverage on Seres Therapeutics in a research note on Thursday, October 12th. They set an “outperform” rating and a $19.00 price objective for the company. Citigroup assumed coverage on Seres Therapeutics in a research note on Thursday, October 12th. They set a “positive” rating and a $19.00 price objective for the company. Finally, Seaport Global Securities reiterated a “buy” rating and set a $20.00 price objective on shares of Seres Therapeutics in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. Seres Therapeutics has a consensus rating of “Buy” and an average target price of $18.00.

COPYRIGHT VIOLATION NOTICE: “Seres Therapeutics Inc (MCRB) Shares Bought by Northern Trust Corp” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://ledgergazette.com/2017/12/13/seres-therapeutics-inc-mcrb-shares-bought-by-northern-trust-corp.html.

Seres Therapeutics Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply